Daily Chart: α-synuclein pipeline for Parkinson's

Roche's disclosure Wednesday that its anti-α-synuclein mAb missed the primary endpoint in a Phase II trial has cast doubt on the future of the therapeutic class' lead candidate. At least 13 other pro...